Primary Biliary Cholangitis
Conditions
Brief summary
This study is a Phase 2a First-in-Human (FIH) clinical trial to assess the safety, tolerability, pharmacodynamics (PD), and efficacy of multiple ascending doses of CNP-104. The study consists of a 120 day primary study followed by a 20 month long-term safety and durability of response follow-up period.
Detailed description
Subjects ages 18-75 with primary biliary cholangitis will be screened up to 14 days prior to enrollment into the study. Screening will be completed to assess eligibility, obtain vital signs, collect laboratory samples and PD measurements, and to receive a FibroScan for liver fibrosis. Subjects will additionally complete an initial PBC-40 assessment and begin an Itch Diary, a questionnaire and scoring system to be completed by the patient every morning and evening through Day 120 and then monthly through end of study. Subjects who meet all inclusion and no exclusion criteria after completing the screening visit will be enrolled in the study. Subjects will be randomized on Day 1 in a 1:1 ratio to receive either CNP-104 or Placebo (0.9% Sodium Chloride USP) by intravenous (IV) infusion. Subjects will be administered CNP-104 or Placebo on Day 1 and on Day 8. This study was originally designed with 2 cohorts, Cohort 1 comprised of 6 subjects randomized 1:1 to placebo or 4 mg/kg, and Cohort 2 comprised of up to 34 subjects randomized 1:1 to placebo or 8 mg/kg. Under Protocol Amendment 6 (v7.0), the remaining subjects for Cohort 2 (approximately 16) will be randomized 1:3:1 to placebo, 4 mg/kg, and 8 mg/kg respectively. Subjects will remain in the clinic on Day 1 and Day 8 from the time of admission (prior to administration of CNP-104 or Placebo) through the final procedure conducted 4 hours post-dose that same day unless an infusion reaction, or other adverse event, requires an extended duration of monitoring. Subjects will be discharged if safety parameters are acceptable to the investigator. Seven days after the second administration of CNP-104 or Placebo, subjects must return to the clinic for collection of safety labs, PD measurements, and assessment of AEs and medication changes. Subjects will continue to be followed for 2 years to assess safety, pharmacodynamics, and immunogenicity during the Post-Dosing period.
Interventions
DRUGCNP-104
CNP-104 is comprised of PDC-E2 peptide dispersed within a negatively charged polymer matrix of poly (lactic-co-glycolic acid) (PLGA) particles at a target concentration of \~1 μg of PDC-E2 peptide per mg of PLGA particles.
DRUGPlacebo
CNP-104 Placebo
Sponsors
COUR Pharmaceutical Development Company, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Subjects who are willing and able to provide Institutional Review Board (IRB) approved written informed consent and privacy language as per national regulations. 2. Men and non-pregnant women, ages 18-75 years inclusive. 3. Subjects with a PBC diagnosis as demonstrated by the presence of 2 or more of the following 3 diagnostic factors: 1. Alkaline phosphatase \> 1.5× ULN for at least 6 months 2. Positive AMA titer or, if AMA negative or in low titer (\<1:40), positive PBC-specific antibodies (anti-GP210 and/or anti-SP100 and/or antibodies against the major M2 components \[PDC-E2, 2-oxo-glutaric acid dehydrogenase complex\]) 3. Liver biopsy findings consistent with PBC 4. Subjects who are unresponsive to UDCA and/or OCA after 6 months of treatment at a stable dose as measured by ALP \> 1.5× ULN. 5. For subjects on any medication used to treat the symptoms of PBC (ex. UDCA, OCA, seladelpar), subjects must be on a stable dose for a minimum of 3 months prior to enrollment and must agree not to change their dose through study Day 60 unless reviewed by the medical monitor and approved by the site investigator. 6. Subjects with ALP \> 1.5× ULN. 7. Subjects with AST and ALT \< 5× ULN. 8. Subjects with hemoglobin ≥ 10 g/dL. 9. Subjects with total bilirubin \< 2× ULN. 10. Men and women of child-bearing potential (WOCBP) must agree to practice a highly effective method of contraception that may include, but is not limited to, abstinence, sex only with persons of the same sex, monogamous relationship with vasectomized partner, vasectomy, hysterectomy, bilateral tubal ligation, licensed hormonal methods, intrauterine device (IUD) beginning at the time of screening through Day 90. 11. Female subjects who agree not to donate ova starting at initial screening and through Day 90. 12. Male subjects who agree to not donate sperm starting at screening and through Day 90.
Exclusion criteria
1. Subjects with a Class B or Class C Child-Pugh score. 2. Subjects with concomitant liver diseases including chronic viral hepatitis B or C, autoimmune hepatitis, PSC, alcoholic liver disease, Wilson's disease, hemochromatosis, or Gilbert's syndrome. 3. Subjects who have previously undergone liver transplantation. 4. Subjects with decompensated liver disease as defined by the presence or history of any of the following: * MELD score \> 15 * Hepatic encephalopathy * Ascites * Hepatorenal syndrome or serum creatinine \> 2 mg/dL * Total Bilirubin \> 3.0 mg/dL * INR \>1.8 unless on anticoagulation such as Coumadin * History of variceal hemorrhage 5. Subjects with a history of cerebrovascular accident in the past 12 months. 6. Subjects with history of myocardial infarction, as defined by any of the following criteria: * Development of pathological Q waves with or without symptoms * Imaging evidence of a region of loss of viable myocardium that is thinned and fails to contract, in the absence of a non-ischemic cause * Pathological findings of a healed or healing myocardial 7. Subjects with chronic kidney disease, as defined by estimated glomerular filtration rate (eGFR) \< 60 mL/min/1.73 m2 for at least 3 months (per CKD EPI Equation - 2021). 8. Subjects with uncontrolled diabetes, as defined by HbA1c \> 7%. 9. Subjects who have used the following medications: * Methotrexate within 90 days of screening. * Immunotherapy drugs unless approved by the medical monitor. 10. Subjects with a history of tuberculosis or positive PPD skin test. 11. Subjects who have received administration of any live vaccine (other than intranasal Influenza) within 28 days or subunit vaccine within 14 days prior to screening or are planning to receive any vaccination before Day 90. 12. Subjects who have used systemic steroids within 3 months prior to screening. 13. Subjects with laboratory test results at screening or prior to study dosing that are outside the normal limits and considered by the Investigator to be clinically significant. Note: This criterion does not apply to liver function tests. Additionally, clinically significant laboratory test results at screening that are related to the condition (PBC) are acceptable as long as all inclusion and no other
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Frequency of Adverse Events (AEs) and Serious Adverse Events (SAEs) | through Study Completion, an average of 720 Days | Frequency tables will be presented by treatment group for all AEs and SAEs by System Organ Class (SOC) and Preferred Term (PT). Frequency tables will also be produced by treatment group for AEs leading to discontinuation from TP and study, by severity, and by causality. No formal statistical testing will be done |
| Laboratory safety assessments (hematology, serum chemistry, coagulation panel, urinalysis). | through Study Completion, an average of 720 Days | Frequency tables of each assessment abnormalities by grade and treatment will be presented. No formal statistical testing will be done. |
| Serum Cytokines (TNF-α, IL-4, IL-6, IL-10, IL-1β, MCP-1, MIP-1α, IFN-γ) | through CNP-Dosing Period, an average of 15 Days | Frequency tables will be presented by treatment group. No formal statistical testing will be done |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| To assess the change from baseline in Serum Alkaline Phosphatase (ALP) levels, for safety only | through Visit 6, an average of 60 Days and Visit 16, an average of 720 Days | Change from baseline in ALP levels at Day 60 and Day 720 |
| To assess the change from baseline in AMA | through Visit 7, an average of 90 Days and Visit 16, an average of 720 Days | Change from baseline in AMA between placebo and CNP-104 at Day 90 and Day 720 |
| To assess the change from baseline in liver fibrosis by FibroScan | through Visit 7, an average of 90 Days and Visit 16, an average of 720 Days | Change from baseline in liver fibrosis by FibroScan between placebo and CNP-104 at Day 90 and Day 720 |
| To assess the change from baseline in modified PBC-40 score | through Visit 6, an average of 60 Days and Visit 16, an average of 720 Days | Change from baseline in modified PBC-40 score between placebo and CNP-104 at Day 60 and Day 720 |
| To assess the change from baseline in Weekly Mean Itch Score | through Visit 6, an average of 60 Days and Visit 16, an average of 720 D | Change from baseline in Weekly Mean Itch Score between placebo and CNP-104 at Day 60 and Day 720 |
| To assess the change from baseline in liver enzymes (Albumin, Bilirubin (total and direct), ALT, AST, GGT) | through Visit 6, an average of 60 Days and Visit 16, an average of 720 Days | Change from baseline in liver enzymes at Days 60 and 720 |
| To assess the change in antigen specific CD4+ and CD8+ T cells | through Visit 6, an average of 60 Days and Visit 16, an average of 720 Days | Change from baseline in antigen specific CD4+ and CD8+ T at Days 60 and 720 |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORChristopher Bowlus, MD
UC Davis
Outcome results
None listed